Aera Therapeutics

Developer of a health technology platform intended to serve transformative genetic medicines. The company's proprietary protein nanoparticle (PNP) genetic medicine delivery platform leverages the discovery of endogenous, human proteins derived from retroelements that can self-assemble to form capsid-like structures and which can package and transfer nucleic acid cargo, combining the benefits of an endogenous, self-assembling system with the engineerability of a protein-based system and has the potential, helping health sector with researching on genetic medicines across modalities and therapeutic areas.

Lux Capital

🏥 Healthcare